See more : Installed Building Products, Inc. (IBP) Income Statement Analysis – Financial Results
Complete financial analysis of Arbutus Biopharma Corporation (ABUS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arbutus Biopharma Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Pure to Pure Beauty Inc. (PPB.CN) Income Statement Analysis – Financial Results
- INVO Bioscience, Inc. (INVO) Income Statement Analysis – Financial Results
- Codexis, Inc. (0I0X.L) Income Statement Analysis – Financial Results
- Pancontinental Energy NL (PCOGF) Income Statement Analysis – Financial Results
- Curaleaf Holdings, Inc. (CURLF) Income Statement Analysis – Financial Results
Arbutus Biopharma Corporation (ABUS)
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.14M | 39.02M | 10.99M | 6.91M | 6.01M | 5.90M | 10.70M | 1.50M | 24.87M | 15.00M | 15.46M | 14.18M | 16.30M | 21.35M | 13.78M | 9.64M | 15.92M | 13.60M | 13.29M | 12.17M | 2.73M | 5.07M | 3.46M | 1.77M | 1.14M | 1.23M |
| Cost of Revenue | 73.70M | 1.43M | 1.75M | 47.48M | 57.60M | 57.90M | 62.70M | 61.30M | 51.51M | 38.70M | 21.46M | 18.13M | 19.49M | 22.13M | 16.97M | 13.25M | 0.00 | 6.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -55.56M | 37.59M | 9.24M | -40.57M | -51.59M | -52.00M | -52.00M | -59.80M | -26.63M | -23.70M | -5.99M | -3.94M | -3.19M | -779.12K | -3.19M | -3.61M | 15.92M | 7.42M | 13.29M | 12.17M | 2.73M | 5.07M | 3.46M | 1.77M | 1.14M | 1.23M |
| Gross Profit Ratio | -306.26% | 96.34% | 84.05% | -586.74% | -858.26% | -881.36% | -485.98% | -3,986.67% | -107.07% | -158.00% | -38.76% | -27.82% | -19.54% | -3.65% | -23.12% | -37.43% | 100.00% | 54.53% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 73.70M | 84.41M | 65.50M | 47.48M | 57.60M | 57.90M | 62.70M | 61.30M | 51.51M | 38.70M | 21.46M | 18.13M | 0.00 | 22,133.98B | 0.00 | 0.00 | 8.43M | 4.53M | 8.76M | 22.32M | 23.71M | 21.61M | 12.85M | 8.72M | 7.75M | 8.65M |
| General & Administrative | 22.48M | 17.83M | 17.14M | 14.72M | 17.73M | 16.00M | 16.10M | 39.40M | 26.44M | 8.70M | 5.55M | 26.89M | 0.00 | 4.78M | 3.97M | 0.00 | 4.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.48M | 17.83M | 17.14M | 14.72M | 17.73M | 16.00M | 16.10M | 39.40M | 26.44M | 8.70M | 5.55M | 26.89M | 6.18M | 4.78M | 3.97M | 3.62M | 4.44M | 3.85M | 3.78M | 7.76M | 6.78M | 5.52M | 3.10M | 2.25M | 1.57M | 1.33M |
| Other Expenses | 0.00 | 2.23M | 1.87M | 1.98M | 2.03M | 7.30M | 2.20M | 2.50M | -770.00K | -5.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 96.24M | 102.24M | 82.64M | 64.18M | 77.36M | 76.10M | 80.80M | 101.80M | 78.53M | 47.90M | 27.62M | -19.49M | 7.14M | 11.73M | 5.88M | 4.73M | 13.28M | 9.10M | 14.38M | 35.55M | 37.38M | 32.79M | 19.87M | 10.97M | 9.31M | 9.98M |
| Cost & Expenses | 96.24M | 102.24M | 82.64M | 64.18M | 77.36M | 76.10M | 80.80M | 101.80M | 78.53M | 47.90M | 27.62M | -19.49M | 26.63M | 33.86M | 22.85M | 17.98M | 13.28M | 15.29M | 14.38M | 35.55M | 37.38M | 32.79M | 19.87M | 10.97M | 9.31M | 9.98M |
| Interest Income | 5.69M | 2.19M | 127.00K | 741.00K | 2.11M | 3.00M | 1.54M | 1.39M | 674.00K | 853.00K | 540.00K | 138.95K | 122.28K | 106.94K | 156.33K | 738.37K | 1.02M | 316.81K | 439.39K | 750.85K | 1.14M | 1.02M | 1.03M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 459.00K | 1.73M | 2.86M | 4.01M | 2.11M | 200.00K | 261.00K | 0.00 | 0.00 | 0.00 | 0.00 | 47.00K | 76.91K | 0.00 | 0.00 | 0.00 | 0.00 | 1.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.40M | 1.43M | 1.75M | 1.98M | 2.03M | 2.18M | 2.03M | 1.09M | 589.00K | 500.00K | 612.84K | 869.54K | 955.45K | 1.04M | 1.91M | 1.11M | 411.65K | 599.77K | 2.40M | 1.20M | 6.80M | 5.59M | 3.85M | 1.26M | 1.30M | 989.78K |
| EBITDA | -70.99M | -61.86M | -71.64M | -57.81M | -147.32M | -58.95M | -106.45M | -488.07M | -76.72M | -32.44M | -11.54M | 34.18M | -9.06M | -11.05M | -6.74M | -7.23M | 3.05M | 20.97M | 1.31M | -17.90M | -27.76M | -22.06M | -12.57M | -9.41M | -6.87M | -7.76M |
| EBITDA Ratio | -391.30% | -156.41% | -650.92% | -825.79% | -1,489.85% | -1,072.88% | -255.14% | 19,473.33% | -118.68% | -216.00% | -58.78% | 270.46% | -60.33% | -53.71% | -48.88% | -32.29% | 25.58% | -7.06% | 45.45% | -129.31% | -1,016.02% | -434.95% | -374.23% | -449.45% | -602.29% | -632.58% |
| Operating Income | -78.10M | -65.46M | -73.52M | -57.81M | -144.07M | -89.80M | -110.90M | -491.60M | -102.32M | -33.00M | -12.15M | -12.99M | -10.32M | -12.51M | -9.07M | -10.95M | 2.64M | -1.68M | -5.96M | -27.63M | -34.65M | -27.72M | -16.41M | -9.20M | -8.17M | -8.75M |
| Operating Income Ratio | -430.53% | -167.75% | -669.11% | -836.07% | -2,396.84% | -1,522.03% | -1,036.45% | -32,773.33% | -411.38% | -220.00% | -78.59% | -91.62% | -63.32% | -58.61% | -65.79% | -113.58% | 16.57% | -12.36% | -44.83% | -227.08% | -1,268.10% | -546.46% | -474.40% | -520.56% | -716.68% | -713.22% |
| Total Other Income/Expenses | 5.25M | 444.00K | -2.73M | -5.94M | -22.48M | 28.44M | 2.20M | 2.47M | 25.02M | -5.40M | -1.91M | 42.56M | 574.19K | -5.65M | -466.28K | -769.07K | -5.22M | 19.76M | -6.49M | -4.03M | 0.00 | 0.00 | 455.26K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -72.85M | -65.01M | -76.25M | -63.75M | -166.38M | -61.40M | -108.70M | -489.10M | -77.31M | -38.70M | -14.06M | 29.95M | -9.85M | -12.52M | -9.48M | -11.72M | -2.58M | 18.08M | -7.67M | -29.80M | 0.00 | 0.00 | -15.96M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -401.57% | -166.62% | -693.91% | -921.97% | -2,767.91% | -1,040.68% | -1,015.89% | -32,606.67% | -310.80% | -258.00% | -90.95% | 211.19% | -60.44% | -58.64% | -68.81% | -121.56% | -16.22% | 132.89% | -57.72% | -244.89% | 0.00% | 0.00% | -461.24% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 4.44M | 1.10M | 1.47M | -12.66M | -4.30M | -24.30M | -105.00M | -16.19M | 100.00K | 1.91M | 3.72M | -590.69K | -99.82K | 259.76K | 3.38M | 0.00 | -2.31K | 388.32K | 8.95M | -483.80K | -852.14K | -2.33M | 0.00 | 0.40 | 0.03 |
| Net Income | -72.85M | -69.46M | -77.35M | -65.21M | -153.72M | -57.10M | -84.40M | -384.10M | -61.12M | -38.80M | -14.06M | 29.95M | -9.73M | -12.41M | -9.33M | -11.72M | -2.58M | 18.08M | -8.06M | -28.05M | -34.08M | -26.79M | -14.02M | -9.20M | -8.17M | -8.75M |
| Net Income Ratio | -401.57% | -178.01% | -703.96% | -943.17% | -2,557.36% | -967.80% | -788.79% | -25,606.67% | -245.73% | -258.67% | -90.95% | 211.19% | -59.69% | -58.14% | -67.68% | -121.56% | -16.22% | 132.90% | -60.64% | -230.49% | -1,247.26% | -528.27% | -405.13% | -520.56% | -716.68% | -713.22% |
| EPS | -0.44 | -0.46 | -0.73 | -0.86 | -2.69 | -1.03 | -1.54 | -7.24 | -1.34 | -1.80 | -0.92 | 2.16 | -0.86 | -1.20 | -0.90 | -1.44 | -0.54 | 4.68 | -1.04 | -3.64 | -4.78 | -4.08 | -2.76 | -1.87 | -2.90 | -4.05 |
| EPS Diluted | -0.44 | -0.46 | -0.73 | -0.86 | -2.69 | -1.03 | -1.54 | -7.24 | -1.34 | -1.73 | -0.92 | 2.07 | -0.86 | -1.20 | -0.90 | -1.44 | -0.54 | 4.68 | -1.04 | -3.64 | -4.78 | -4.08 | -2.76 | -1.87 | -2.90 | -4.05 |
| Weighted Avg Shares Out | 165.96M | 150.94M | 106.24M | 75.84M | 57.09M | 55.30M | 54.69M | 53.05M | 45.45M | 21.58M | 15.29M | 13.73M | 11.32M | 10.33M | 10.33M | 8.12M | 4.77M | 3.86M | 7.71M | 7.70M | 7.13M | 6.57M | 5.07M | 4.93M | 2.82M | 2.16M |
| Weighted Avg Shares Out (Dil) | 165.96M | 150.94M | 106.24M | 75.84M | 57.09M | 55.30M | 54.72M | 53.05M | 45.46M | 22.44M | 15.30M | 14.32M | 11.32M | 10.33M | 10.33M | 8.12M | 4.77M | 3.86M | 7.71M | 7.70M | 7.13M | 6.57M | 5.07M | 4.93M | 2.82M | 2.16M |
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection,...
Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Significantly greater mean declines in HBsAg levels (p
Arbutus to Present at Jefferies London Healthcare Conference
WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection,...
Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript
Arbutus Biopharma Corporation (NASDAQ:ABUS ) Q3 2024 Results Conference Call November 6, 2024 8:45 AM ET Company Participants Lisa Caperelli - VP, Investor Relations Mike McElhaugh - Interim President, CEO & Director Karen Sims - Chief Medical Officer Dave Hastings...
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.12 per share a year ago.
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
WARMINSTER, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection,...
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
WARMINSTER, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection,...
Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year?
Here is how Arbutus Biopharma (ABUS) and Astrazeneca (AZN) have performed compared to their sector so far this year.
Arbutus to Participate in Two Upcoming Investor Conferences
WARMINSTER, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection,...
Source: https://incomestatements.info
Category: Stock Reports